Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00074529
First received: December 15, 2003
Last updated: July 22, 2014
Last verified: July 2014

December 15, 2003
July 22, 2014
November 2003
January 2006   (final data collection date for primary outcome measure)
Cognitive function over 12 month period; safety and tolerability [ Time Frame: over 12 month period ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00074529 on ClinicalTrials.gov Archive Site
AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog. [ Time Frame: over a 6 month and 12 month period ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Alzheimer's Disease
Drug: MK0677
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
512
January 2006
January 2006   (final data collection date for primary outcome measure)
  • Patients must have probable Alzheimer's disease of mild or moderate severity.
  • A brain scan and laboratory results must be consistent with Alzheimer's disease.
  • The patient must be otherwise medically healthy.
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00074529
0677-030, Formally-BG0812AZ, MK0677-030, 2006_412
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP